R. Lor Randall, MD, FACS, is the David Linn Endowed Chair for Orthopedic Surgery and chair of the Department of Orthopedic Surgery as well as a professor at the University of California Davis.

R. Lor Randall, MD, FACS, professor and The David Linn Endowed Chair for Orthopaedic Surgery and professor and chair of the Department of Orthopaedic Surgery, University of California Davis Health, discusses the SAFETY trial (NCT03944798) in soft tissue sarcoma.

The SAFETY trial will evaluate the effectiveness of chest computerized tomography (CT) versus chest radiograph in patients with primary extremity sarcoma that has metastasized to the lungs. Currently, when soft tissue sarcoma metastasizes to the lungs, patients undergo chest imaging via a chest radiograph or a chest CT scan; however, it is unknown whether the imaging should be done every 3 months or every 6 months and whether a chest radiograph or CT scan is best.

While a chest radiograph provides results more quickly and exposes patients to less radiation, a chest CT scan provides a more detailed image, says Randall. This trial may shed light on whether a chest CT is needed or whether patients could be spared unnecessary radiation, concludes Randall.

Videos

R. Lor Randall, MD, FACS, discusses the SAFETY trial (NCT03944798) in soft tissue sarcoma.

Dr. Randall on the SAFETY Trial in Soft Tissue Sarcoma

R. Lor Randall, MD, FACS, professor and The David Linn Endowed Chair for Orthopaedic Surgery, University of California Davis Health, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.

Research is looking into deep sequencing tumors to look for mutations that can be targeted with the cadre of biotargeting agents in primary bone and tissue sarcomas, explains Randall. Patients with these tumors eligible for chemotherapy will receive it in a conventional form. If they fail conventional chemotherapy, they will move on to more targeted agents, says Randall.

At the University of California Davis Health, when sarcoma is diagnosed based on biopsy, some of the original tumor is stored for precision medicine treatments, concludes Randall.

R. Lor Randall, MD, FACS, discusses ongoing research in sequencing the tumors of patients with primary bone or tissue sarcomas.

Dr. Randall of Tumor Sequencing Research in Sarcomas

R. Lor Randall, MD, FACS, professor and The David Linn Endowed Chair for Orthopaedic Surgery, University of California Davis Health, discusses the use of pexidartinib (Turalio), which was recently 

, in the treatment of patients with tenosynovial giant cell tumor (TGCT).

In TGCT, there are 2 subclasses: pigmented villonodular synovitis and giant cell tumor of the tendon sheath, says Randall. For the most part, these are benign conditions that grow very aggressively around the knee and other areas, which can be very debilitating for patients, he explains.

Until recently, the standard of care for patients with TGCT has been surgical removal, but over a period of time the tumor grows back, adds Randall. The phase III ENLIVEN trial showed that pexidartinib, a CSF1R inhibitor, can target this disease and shrink the tumor. Pexidartinib does not entirely eliminate the tumor, but it can help reduce its size and assist with symptom reduction, concludes Randall.

R. Lor Randall, MD, FACS, discusses using pexidartinib to treat tenosynovial giant cell tumor.

R. Lor Randall, MD, FACS

Articles

Dr. Randall on the SAFETY Trial in Soft Tissue Sarcoma

Dr. Randall of Tumor Sequencing Research in Sarcomas

Dr. Randall on Using Pexidartinib to Treat Tenosynovial Giant Cell Tumor